{
    "index": 286,
    "label": "Structured scientific or technical content",
    "attributes": "formal structure, detailed data tables, methodology descriptions, statistical results, references to figures and tables, domain-specific terminology",
    "reasoning": "The texts within the samples exhibit formal structure typically associated with scientific or technical documents, such as detailed data tables, specific enumeration of activities, methodology descriptions, inclusion of statistical results, references to figures and tables, and domain-specific terminology. This is in stark contrast to the samples, which consist of informal and conversational language with no such structured and academic presentation.",
    "density": 0.0017889257429736026,
    "confidence": 100.0,
    "high_act_samples": [
        {
            "text": "###### \n\nData quality assessment (DQA) activities implementation schedule, 2017\n\n  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n  Phase 1: preparation                  January 2-March 14, 2017\n  ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n                                        Identifying resources, partners, and staff, scheduling activities, venues, and transport, finalizing protocol and data collection tools (printed or electronic).",
            "act": 0.24515581130981445
        },
        {
            "text": "STROBE-Punkte                                                                                                                                                                                                                                                                                                                                    RECORD-Punkte\n  ------------------------------------------------------------------- ----- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n  **Titel und Abstract**                                                                                                                                                                                                                                                                                                                                                                                                     \n\n                                                                      1     \\(a\\) Machen Sie das Studiendesign im Titel oder Abstract kenntlich, indem Sie daf\u00fcr einen allgemein gebr\u00e4uchlichen Begriff verwenden\\                                                                                                                                                                                                           RECORD 1.1: Der verwendete Datentyp sollte im Titel oder Abstract angegeben werden.",
            "act": 0.23335237801074982
        },
        {
            "text": "Tabelle 1\n\n  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n                                                                      Nr.",
            "act": 0.22973431646823883
        },
        {
            "text": "-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\nFractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (\u00c5^2^) {#tablewrapcoords}\n==================================================================================================\n\n  ------- --------------- --------------- ------------- -------------------- ------------\n          *x*             *y*             *z*           *U*~iso~\\*/*U*~eq~   Occ.",
            "act": 0.22705566883087158
        },
        {
            "text": "----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n[^1]: Die beiden letztgenannten Autoren haben zu gleichen Teilen zu dieser Arbeit beigetragen.",
            "act": 0.22705566883087158
        },
        {
            "text": "*\"*                          \n  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\nThe active transport lesson was interactive and all elements of the lesson were made as visually appealing as possible for the older adolescents (see [Fig 2](#pone.0168594.g002){ref-type=\"fig\"}) \\[[@pone.0168594.ref034]\\].",
            "act": 0.22492992877960205
        },
        {
            "text": "Liga in 2008 as the new third tier, below the 2.",
            "act": 0.21912653744220734
        },
        {
            "text": "Bundesliga S\u00fcd (the southern division of 2.",
            "act": 0.20200294256210327
        },
        {
            "text": "[](pone.0168594.t002){#pone.0168594.t002g}\n\n  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n  Feedback semi-structured group interviews                                                                                                                                                                                             Adaptations intervention\n  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n  Stronger emphasis should be put on the focus of the lesson (i.e.",
            "act": 0.19532173871994019
        },
        {
            "text": "[](pone.0191608.t002){#pone.0191608.t002g}\n\n  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n                                                                                    All participants with negative sputum index results at enrolment who were subsequently started on TB treatment\\                 \n  --------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- ------------- -------------\n  **Characteristics at enrolment**                                                                                                                                                                                  \n\n  \u00a0\u00a0\u00a0\u00a0Female gender, n (%)                                                          79 (47)                                                                                                           39 (48)       25 (41)\n\n  \u00a0\u00a0\u00a0\u00a0Age in years, median (IQR)                                                    37 (31--45)                                                                                                       36 (30--45)   37 (31--43)\n\n  \u00a0\u00a0\u00a0\u00a0Residing in a rural area, n (%)                                               72 (43)                                                                                                           32 (39)       27 (45)\n\n  \u00a0\u00a0\u00a0\u00a0HIV status at enrolment                                                                                                                                                                                       \n\n  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0HIV positive before or at enrolment/HIV status known, n/N, (%)            120/137 (88)                                                                                                      59/78 (76)    46/50 (92)\n\n  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0on ART, among those HIV positive, n/N (%)                                 30/120 (25)                                                                                                       10/59 (17)    14/46 (30)\n\n  \u00a0\u00a0\u00a0\u00a0Previous TB, n (%)                                                            41 (25)                                                                                                           22/82 (27)    16 (26)\n\n  \u00a0\u00a0\u00a0\u00a0Karnofsky score \\<80, n (%)                                                   41 (25)                                                                                                           46/82 (47)    16 (27)\n\n  \u00a0\u00a0\u00a0\u00a0Body mass index \\<18.5, kg/m^2^, n (%)                                        23 (14)                                                                                                           9 (11)        11 (18)\n\n  \u00a0\u00a0\u00a0\u00a0XTEND study arm                                                                                                                                                                                               \n\n  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Smear microscopy                                                          113 (68)                                                                                                          61 (74)       43 (72)\n\n  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Xpert                                                                     54 (32)                                                                                                           21 (26)       17 (28)\n\n  **Health seeking behaviour and symptoms prior to and at enrolment**                                                                                                                                               \n\n  \u00a0\u00a0\u00a0\u00a0Participants with duration of symptoms \\> 2 weeks prior to enrolment, n (%)   109 (65)                                                                                                          47 (57)       14 (23)\n\n  \u00a0\u00a0\u00a0\u00a0Enrolment visit was first health seeking visit for TB symptoms, n (%)         111 (66)                                                                                                          43 (52)       30 (50)\n\n  \u00a0\u00a0\u00a0\u00a0Visits to health care provider prior to enrolment, median (IQR)               1 (0--2)                                                                                                          1.5 (1--3)    1 (0--2)\n\n  \u00a0\u00a0\u00a0\u00a0Provider from whom participant first sought help for presenting symptoms                                                                                                                                      \n\n  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Public clinic, n, %                                                       126 (75)                                                                                                          66 (80)       46 (77)\n\n  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Pharmacy, n (%)                                                           20 (12)                                                                                                           8 (10)        9 (15)\n\n  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Private doctor/other, n(%)                                                15 (9)                                                                                                            5 (7)         5 (8)\n\n  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Public Hospital, n (%)                                                    5 (3)                                                                                                             3 (5)         0\n\n  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Traditional healer, n (%)                                                 1 (1)                                                                                                             0             0\n\n  \u00a0\u00a0\u00a0\u00a0Reason for visit to PHC at which enrolment took place                                                                                                                                                         \n\n  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0TB symptoms, n (%)                                                        140 (84)                                                                                                          71 (87)       51 (85)\n\n  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0HIV testing or routine visit, n (%)                                       15 (9)                                                                                                            8 (8)         5(8)\n\n  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Chronic disease routine visit/other, n (%)                                12 (7)                                                                                                            3 (4)         4 (7)\n\n  \u00a0\u00a0\u00a0\u00a0Number of symptoms at enrolment                                                                                                                                                                               \n\n  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0None, n (%)                                                               3 (2)                                                                                                             1 (1)         2 (3)\n\n  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a01--2, n (%)                                                               61 (37)                                                                                                           29 (35)       22 (37)\n\n  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a03--4, n (%)                                                               103 (62)                                                                                                          52 (64)       36 (60)\n  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n\\* A subset of the group n = 167 who met the definition for empiric TB treatment initiation as defined in [Table 1](#pone.0191608.t001){ref-type=\"table\"}.",
            "act": 0.18849974870681763
        },
        {
            "text": "-------------------------------------------\nBatch: 1\n-------------------------------------------\n+-------------------+-----+---+----+\n|wtimestamp         |value|key|dkey|\n+-------------------+-----+---+----+\n|2017-08-09 10:00:10|10   |0.0|1.0 |\n+-------------------+-----+---+----+\n\n-------------------------------------------\nBatch: 2\n-------------------------------------------\n+----------+-----+---+----+\n|wtimestamp|value|key|dkey|\n+----------+-----+---+----+\n+----------+-----+---+----+\n\n-------------------------------------------\nBatch: 3\n-------------------------------------------\n+-------------------+-----+---+----+\n|wtimestamp         |value|key|dkey|\n+-------------------+-----+---+----+\n|2017-08-09 10:00:20|20   |0.0|0.0 |\n+-------------------+-----+---+----+\n\n-------------------------------------------\nBatch: 4\n-------------------------------------------\n+----------+-----+---+----+\n|wtimestamp|value|key|dkey|\n+----------+-----+---+----+\n+----------+-----+---+----+\n\n-------------------------------------------\nBatch: 5\n-------------------------------------------\n+-------------------+-----+---+----+\n|wtimestamp         |value|key|dkey|\n+-------------------+-----+---+----+\n|2017-08-09 10:00:30|10   |0.0|1.0 |\n+-------------------+-----+---+----+\n\n-------------------------------------------\nBatch: 6\n-------------------------------------------\n+----------+-----+---+----+\n|wtimestamp|value|key|dkey|\n+----------+-----+---+----+\n+----------+-----+---+----+\n\n-------------------------------------------\nBatch: 7\n-------------------------------------------\n+----------+-----+---+----+\n|wtimestamp|value|key|dkey|\n+----------+-----+---+----+\n+----------+-----+---+----+\n\n-------------------------------------------\nBatch: 8\n-------------------------------------------\n+-------------------+-----+---+----+\n|wtimestamp         |value|key|dkey|\n+-------------------+-----+---+----+\n|2017-08-09 11:00:30|40   |0.0|0.0 |\n+-------------------+-----+---+----+\n\nI know watermark drop state by use maxevent-time in window, but in dropduplicate, I don't know how it clear state?",
            "act": 0.18833021819591522
        },
        {
            "text": "[](pone.0168594.t001){#pone.0168594.t001g}\n\n  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n  Element of the active transport lesson                                                                                   Description                                                                                                                                                                                                                                                                     Determinant(s)      Method(s)\n  ------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- ------------------------------\n  1\\) Brief introduction                                                                                                   The purpose of the lesson was explained and importance to always choose consciously between transport modes, even after obtaining a driving licence, was stressed.",
            "act": 0.18449655175209045
        },
        {
            "text": "[](pone.0191608.t003){#pone.0191608.t003g}\n\n  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n                                                                                                                                               All participants with negative sputum index results at enrolment who were subsequently started on TB treatment\\                   \n  -------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- --------------- ------------------\n  **Investigations for TB initiated by PHC staff after enrolment in XTEND**                                                                                                                                                                                                      \n\n  \u00a0\u00a0\u00a0\u00a0Sputum culture done, n (%)                                                                                                               64 (38)                                                                                                           23 (28)         42 (70)\n\n  \u00a0\u00a0\u00a0\u00a0Documented chest radiography, n (%)                                                                                                      58 (35)                                                                                                           51 (62)         9 (15)\n\n  \u00a0\u00a0\u00a0\u00a0Undocumented chest radiography, n (%) (patient reported at interview)                                                                    29 (17)                                                                                                           10 (11)         6 (10)\n\n  \u00a0\u00a0\u00a0\u00a0Any admission to hospital, n (%)                                                                                                         27 (22)                                                                                                           70 (85)         9 (15)\n\n  Algorithm followed (any of documented CXR, culture, or referral for hospital), n (%)                                                         106 (63)                                                                                                          58 (71)         45 (75)\n\n  **TB treatment initiation**                                                                                                                                                                                                                                                    \n\n  Reason for TB treatment start (as defined in [Table 1](#pone.0191608.t001){ref-type=\"table\"})                                                                                                                                                                                  \n\n  \u00a0\u00a0\u00a0\u00a0Clinical assessment compatible with TB, n (%)                                                                                            19 (11)                                                                                                           19 (23)         1 (2)\n\n  \u00a0\u00a0\u00a0\u00a0Chest radiography compatible with TB (documented or undocumented), n (%)                                                                 63 (38)                                                                                                           63 (77)         10 (17)\n\n  \u00a0\u00a0\u00a0\u00a0Positive sputum test for TB^z^, n (%)                                                                                                    49 (29)                                                                                                           0               45 (75)\n\n  \u00a0\u00a0\u00a0\u00a0Extra-pulmonary TB diagnosed at higher level of care, n (%)                                                                              9 (5)                                                                                                             0               2 (3)\n\n  \u00a0\u00a0\u00a0\u00a0Assessment at a higher level of care leading to TB treatment initiation, n (%)                                                           19 (11)                                                                                                           0               2 (3)\n\n  \u00a0\u00a0\u00a0\u00a0Unclear^y^, n (%)                                                                                                                        8 (5)                                                                                                             0               0\n\n  TB treatment started 'empirically' (i.e.",
            "act": 0.17671066522598267
        },
        {
            "text": "\" I NEED TO BE SOMEWHERE, MR.",
            "act": 0.1656550019979477
        },
        {
            "text": "\"It's just that I got work commitments and I've got to be in the city by tonight.\"",
            "act": 0.16113683581352234
        },
        {
            "text": "-------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n  Prestroke dementia                           Assessment was based on interviews with the persons and a knowledgeable informant.",
            "act": 0.1534786820411682
        },
        {
            "text": "Materials and methods {#s4}\n=====================\n\n  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n  Reagent type\\             Designation                          Source or reference   Identifiers                                                                                                                                   Additional information\n  (species) or resource                                                                                                                                                                                                              \n  ------------------------- ------------------------------------ --------------------- --------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------\n  Gene (mouse)              Spen                                 RefSeq                [NM_019763.2](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&db=Nucleotide&term=NM_019763&doptcmdl=GenBank&tool=genome.ucsc.edu)   \n\n  Cell line (mouse)         TXY WT and TXY deltaA                Dr. Edith Heard       Xist-WT and Xist-deltaA                                                                                                                       Cell lines have a doxycycline inducible Xist gene + / - the A repeat region\n\n  Cell line (mouse)         HATX WT and HATX Spen KO             Dr. Anton Wutz        WT, *Spen* KO                                                                                                                                 KO cells have a deletion\\\n                                                                                                                                                                                                                                     of the majority of the Spen gene.",
            "act": 0.15080687403678894
        },
        {
            "text": "I need to stop caring.",
            "act": 0.14897239208221436
        },
        {
            "text": "\\- awareness        \\- persuasive communication\n  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\nThirdly, the active transport lesson was developed by two researchers (HV and DS).",
            "act": 0.14760960638523102
        },
        {
            "text": "-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\nFractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (\u00c5^2^) {#d1e561}\n==================================================================================================\n\n  ------ ------------- --------------- ------------- -------------------- --\n         *x*           *y*             *z*           *U*~iso~\\*/*U*~eq~   \n  O1     0.37595 (5)   \u22120.09851 (12)   0.25430 (5)   0.0178 (2)           \n  O2     0.46409 (5)   0.36094 (13)    0.13692 (6)   0.0223 (2)           \n  O3     0.48126 (5)   0.09177 (13)    0.11188 (5)   0.0203 (2)           \n  O4     0.28470 (5)   0.53164 (13)    0.53959 (6)   0.0195 (2)           \n  N1     0.35473 (6)   0.20560 (15)    0.29392 (7)   0.0167 (3)           \n  H1N    0.3533 (9)    0.090 (2)       0.2929 (10)   0.033 (5)\\*          \n  C1     0.51239 (8)   \u22120.1830 (2)     0.07643 (9)   0.0261 (4)           \n  H1A    0.558974      \u22120.151115       0.094154      0.039\\*              \n  H1B    0.495675      \u22120.158824       0.020257      0.039\\*              \n  H1C    0.507565      \u22120.305845       0.085797      0.039\\*              \n  C2     0.47443 (7)   \u22120.08168 (19)   0.12051 (8)   0.0186 (3)           \n  C3     0.43857 (7)   \u22120.14438 (18)   0.16567 (8)   0.0179 (3)           \n  H3     0.433601      \u22120.265332       0.168807      0.021\\*              \n  C4     0.40712 (6)   \u22120.03355 (17)   0.20989 (8)   0.0154 (3)           \n  C5     0.41363 (6)   0.14995 (17)    0.20071 (7)   0.0153 (3)           \n  C6     0.45203 (6)   0.21302 (18)    0.15026 (8)   0.0169 (3)           \n  C7     0.38639 (6)   0.26807 (18)    0.24515 (8)   0.0162 (3)           \n  C8     0.39081 (7)   0.45891 (18)    0.23821 (8)   0.0203 (3)           \n  H8C    0.374124      0.492541        0.183088      0.031\\*              \n  H8B    0.436806      0.495022        0.257827      0.031\\*              \n  H8A    0.364402      0.514294        0.269172      0.031\\*              \n  C9     0.33460 (7)   0.29881 (17)    0.35356 (8)   0.0164 (3)           \n  C10    0.26863 (7)   0.30913 (17)    0.35148 (8)   0.0171 (3)           \n  H10    0.236228      0.263353        0.308090      0.020\\*              \n  C11    0.24977 (7)   0.38655 (17)    0.41296 (8)   0.0173 (3)           \n  H11    0.204561      0.393367        0.411788      0.021\\*              \n  C12    0.29738 (7)   0.45369 (17)    0.47593 (8)   0.0166 (3)           \n  C13    0.36385 (7)   0.44554 (18)    0.47719 (8)   0.0193 (3)           \n  H13    0.396300      0.493437        0.519946      0.023\\*              \n  C14    0.38224 (7)   0.36797 (18)    0.41637 (8)   0.0186 (3)           \n  H14    0.427417      0.361699        0.417316      0.022\\*              \n  C15    0.21698 (7)   0.56107 (18)    0.53868 (8)   0.0193 (3)           \n  H15A   0.192613      0.451001        0.533117      0.023\\*              \n  H15B   0.195276      0.637069        0.494438      0.023\\*              \n  C16    0.21851 (7)   0.64530 (19)    0.61584 (9)   0.0224 (3)           \n  H16A   0.245376      0.749760        0.622067      0.034\\*              \n  H16B   0.237520      0.565599        0.658818      0.034\\*              \n  H16C   0.173613      0.675273        0.616796      0.034\\*              \n  ------ ------------- --------------- ------------- -------------------- --\n\nAtomic displacement parameters (\u00c5^2^) {#d1e1074}\n=====================================\n\n  ----- ------------ ------------ ------------ ------------- ------------- -------------\n        *U*^11^      *U*^22^      *U*^33^      *U*^12^       *U*^13^       *U*^23^\n  O1    0.0187 (5)   0.0183 (5)   0.0179 (5)   \u22120.0034 (4)   0.0075 (4)    0.0023 (4)\n  O2    0.0232 (5)   0.0233 (5)   0.0203 (5)   \u22120.0055 (4)   0.0056 (4)    0.0058 (4)\n  O3    0.0226 (5)   0.0243 (5)   0.0155 (5)   \u22120.0066 (4)   0.0077 (4)    \u22120.0002 (4)\n  O4    0.0167 (5)   0.0222 (5)   0.0200 (5)   0.0015 (4)    0.0058 (4)    \u22120.0013 (4)\n  N1    0.0170 (6)   0.0156 (6)   0.0179 (6)   \u22120.0009 (5)   0.0052 (5)    0.0022 (5)\n  C1    0.0239 (8)   0.0343 (9)   0.0214 (8)   \u22120.0039 (7)   0.0083 (6)    \u22120.0058 (6)\n  C2    0.0168 (7)   0.0232 (7)   0.0133 (7)   \u22120.0027 (6)   \u22120.0003 (6)   \u22120.0006 (6)\n  C3    0.0180 (7)   0.0186 (7)   0.0155 (7)   \u22120.0022 (6)   0.0017 (6)    0.0012 (5)\n  C4    0.0116 (6)   0.0202 (7)   0.0121 (6)   \u22120.0029 (5)   \u22120.0008 (5)   0.0018 (5)\n  C5    0.0125 (6)   0.0188 (7)   0.0122 (6)   \u22120.0023 (5)   \u22120.0008 (5)   0.0024 (5)\n  C6    0.0139 (7)   0.0232 (7)   0.0108 (6)   \u22120.0028 (6)   \u22120.0016 (5)   0.0022 (5)\n  C7    0.0118 (6)   0.0199 (7)   0.0135 (7)   \u22120.0020 (5)   \u22120.0022 (5)   0.0035 (5)\n  C8    0.0221 (7)   0.0183 (7)   0.0197 (7)   \u22120.0007 (6)   0.0040 (6)    0.0036 (5)\n  C9    0.0183 (7)   0.0137 (6)   0.0175 (7)   0.0006 (5)    0.0056 (6)    0.0039 (5)\n  C10   0.0170 (7)   0.0148 (6)   0.0175 (7)   \u22120.0012 (5)   0.0012 (6)    0.0031 (5)\n  C11   0.0146 (7)   0.0164 (7)   0.0209 (7)   0.0020 (5)    0.0045 (6)    0.0038 (5)\n  C12   0.0199 (7)   0.0141 (6)   0.0166 (7)   0.0022 (5)    0.0063 (6)    0.0026 (5)\n  C13   0.0170 (7)   0.0197 (7)   0.0198 (7)   \u22120.0002 (6)   0.0024 (6)    \u22120.0001 (6)\n  C14   0.0137 (7)   0.0213 (7)   0.0210 (7)   0.0010 (6)    0.0048 (6)    0.0030 (6)\n  C15   0.0165 (7)   0.0189 (7)   0.0238 (8)   0.0021 (5)    0.0079 (6)    0.0037 (6)\n  C16   0.0221 (7)   0.0211 (7)   0.0266 (8)   0.0021 (6)    0.0112 (6)    0.0024 (6)\n  ----- ------------ ------------ ------------ ------------- ------------- -------------\n\nGeometric parameters (\u00c5, \u00ba) {#d1e1484}\n===========================\n\n  ------------------- -------------- ----------------------- --------------\n  O1---C4             1.2585 (16)    C8---H8C                0.9800\n  O2---C6             1.2154 (17)    C8---H8B                0.9800\n  O3---C2             1.3698 (17)    C8---H8A                0.9800\n  O3---C6             1.3988 (18)    C9---C10                1.385 (2)\n  O4---C12            1.3680 (16)    C9---C14                1.392 (2)\n  O4---C15            1.4427 (16)    C10---C11               1.392 (2)\n  N1---C7             1.3182 (18)    C10---H10               0.9500\n  N1---C9             1.4358 (18)    C11---C12               1.387 (2)\n  N1---H1N            0.902 (19)     C11---H11               0.9500\n  C1---C2             1.486 (2)      C12---C13               1.398 (2)\n  C1---H1A            0.9800         C13---C14               1.378 (2)\n  C1---H1B            0.9800         C13---H13               0.9500\n  C1---H1C            0.9800         C14---H14               0.9500\n  C2---C3             1.332 (2)      C15---C16               1.508 (2)\n  C3---C4             1.440 (2)      C15---H15A              0.9900\n  C3---H3             0.9500         C15---H15B              0.9900\n  C4---C5             1.4474 (19)    C16---H16A              0.9800\n  C5---C7             1.427 (2)      C16---H16B              0.9800\n  C5---C6             1.4431 (19)    C16---H16C              0.9800\n  C7---C8             1.4946 (19)                            \n                                                             \n  C2---O3---C6        122.46 (11)    H8C---C8---H8A          109.5\n  C12---O4---C15      118.24 (11)    H8B---C8---H8A          109.5\n  C7---N1---C9        126.68 (12)    C10---C9---C14          120.28 (13)\n  C7---N1---H1N       112.0 (11)     C10---C9---N1           120.22 (12)\n  C9---N1---H1N       120.3 (11)     C14---C9---N1           119.34 (12)\n  C2---C1---H1A       109.5          C9---C10---C11          120.03 (13)\n  C2---C1---H1B       109.5          C9---C10---H10          120.0\n  H1A---C1---H1B      109.5          C11---C10---H10         120.0\n  C2---C1---H1C       109.5          C12---C11---C10         119.60 (13)\n  H1A---C1---H1C      109.5          C12---C11---H11         120.2\n  H1B---C1---H1C      109.5          C10---C11---H11         120.2\n  C3---C2---O3        121.42 (13)    O4---C12---C11          124.71 (13)\n  C3---C2---C1        126.45 (14)    O4---C12---C13          115.09 (12)\n  O3---C2---C1        112.10 (12)    C11---C12---C13         120.19 (13)\n  C2---C3---C4        121.71 (13)    C14---C13---C12         119.94 (13)\n  C2---C3---H3        119.1          C14---C13---H13         120.0\n  C4---C3---H3        119.1          C12---C13---H13         120.0\n  O1---C4---C3        119.56 (12)    C13---C14---C9          119.95 (13)\n  O1---C4---C5        123.19 (13)    C13---C14---H14         120.0\n  C3---C4---C5        117.25 (12)    C9---C14---H14          120.0\n  C7---C5---C6        119.89 (12)    O4---C15---C16          106.17 (11)\n  C7---C5---C4        120.58 (12)    O4---C15---H15A         110.5\n  C6---C5---C4        119.38 (13)    C16---C15---H15A        110.5\n  O2---C6---O3        113.66 (12)    O4---C15---H15B         110.5\n  O2---C6---C5        128.60 (14)    C16---C15---H15B        110.5\n  O3---C6---C5        117.73 (12)    H15A---C15---H15B       108.7\n  N1---C7---C5        118.27 (13)    C15---C16---H16A        109.5\n  N1---C7---C8        118.28 (13)    C15---C16---H16B        109.5\n  C5---C7---C8        123.44 (12)    H16A---C16---H16B       109.5\n  C7---C8---H8C       109.5          C15---C16---H16C        109.5\n  C7---C8---H8B       109.5          H16A---C16---H16C       109.5\n  H8C---C8---H8B      109.5          H16B---C16---H16C       109.5\n  C7---C8---H8A       109.5                                  \n                                                             \n  C6---O3---C2---C3   0.80 (19)      C4---C5---C7---N1       \u22120.68 (18)\n  C6---O3---C2---C1   \u2212177.59 (11)   C6---C5---C7---C8       4.91 (19)\n  O3---C2---C3---C4   \u22122.3 (2)       C4---C5---C7---C8       \u2212179.52 (12)\n  C1---C2---C3---C4   175.89 (13)    C7---N1---C9---C10      119.67 (15)\n  C2---C3---C4---O1   \u2212177.10 (12)   C7---N1---C9---C14      \u221264.93 (18)\n  C2---C3---C4---C5   2.62 (19)      C14---C9---C10---C11    \u22121.0 (2)\n  O1---C4---C5---C7   2.5 (2)        N1---C9---C10---C11     174.36 (12)\n  C3---C4---C5---C7   \u2212177.19 (12)   C9---C10---C11---C12    0.3 (2)\n  O1---C4---C5---C6   178.11 (12)    C15---O4---C12---C11    \u22125.99 (19)\n  C3---C4---C5---C6   \u22121.60 (18)     C15---O4---C12---C13    173.59 (12)\n  C2---O3---C6---O2   178.87 (11)    C10---C11---C12---O4    \u2212179.66 (12)\n  C2---O3---C6---C5   0.19 (18)      C10---C11---C12---C13   0.8 (2)\n  C7---C5---C6---O2   \u22122.5 (2)       O4---C12---C13---C14    179.28 (12)\n  C4---C5---C6---O2   \u2212178.17 (13)   C11---C12---C13---C14   \u22121.1 (2)\n  C7---C5---C6---O3   175.91 (11)    C12---C13---C14---C9    0.4 (2)\n  C4---C5---C6---O3   0.28 (18)      C10---C9---C14---C13    0.7 (2)\n  C9---N1---C7---C5   167.68 (12)    N1---C9---C14---C13     \u2212174.74 (12)\n  C9---N1---C7---C8   \u221213.4 (2)      C12---O4---C15---C16    179.27 (11)\n  C6---C5---C7---N1   \u2212176.26 (12)                           \n  ------------------- -------------- ----------------------- --------------\n\nHydrogen-bond geometry (\u00c5, \u00ba) {#d1e2193}\n=============================\n\nCg1 is the centroid of the C9--C14 benzene ring.",
            "act": 0.14372724294662476
        },
        {
            "text": "msgstr \"\"\n\"\u0627\u06af\u0631 \u0627\u06cc\u0646 \u06af\u0632\u06cc\u0646\u0647 \u0631\u0627 \u0627\u0646\u062a\u062e\u0627\u0628 \u06a9\u0646\u06cc\u062f\u060c \u067e\u06cc\u0627\u0645\u200c\u0647\u0627\u06cc \u062c\u062f\u06cc\u062f \u0628\u0647 \u062a\u0648\u062c\u0647 \u0634\u0645\u0627 \u0646\u06cc\u0627\u0632 \u062e\u0648\u0627\u0647\u0646\u062f \u062f\u0627\u0634\u062a.\"",
            "act": 0.14249014854431152
        },
        {
            "text": "[](pone.0168594.t004){#pone.0168594.t004g}\n\n                                                                          Response category                                                         Response alternatives                                                          Mean (SD), %\n  ----------------------------------------------------------------------- ------------------------------------------------------------------------- ------------------------------------------------------------------------------ --------------\n  **Active transport lesson**                                                                                                                                                                                                      \n  If you could choose, would you have followed the lesson voluntarily?",
            "act": 0.14129088819026947
        },
        {
            "text": "[](pone.0168594.t003){#pone.0168594.t003g}\n\n  Factor               Number of items                                                                                                            Response category                                        Cronbach \u03b1\n  -------------------- -------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------- ------------\n  Intention            3 items (e.g.",
            "act": 0.1340818554162979
        },
        {
            "text": "[](pone.0191608.t001){#pone.0191608.t001g}\n\n  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n  Criteria used to infer the reason for TB treatment start                                                                                                                                                                                              Inferred reason for TB treatment start                                    Was TB treatment given empirically?",
            "act": 0.13352884352207184
        },
        {
            "text": "------------------------------------------------------------------------------------\n  Distribution of cell cycle   Control   Ang II\\   Ang II (1\u2009*\u03bc*M)            \n                                         1\u2009*\u03bc*M                               \n  ---------------------------- --------- --------- ----------------- -------- --------\n  G~0~/G~1~                    70.56%    68.09%    67.53%            69.79%   72.97%\n\n  G~2~/M                       3.15%     1.87%     2.83%             2.68%    2.79%\n\n  S                            25.63%    30.22%    29.82%            24.72%   24.27%\n  ------------------------------------------------------------------------------------\n\n[^1]: Academic Editor: Honglin Luo",
            "act": 0.12503893673419952
        },
        {
            "text": "Table [1](#T1){ref-type=\"table\"} illustrates an overview of Round 4 and 5 TRP comments on human resources interventions:\n\n###### \n\nRound 4 and 5 comments of the Global Fund\\'s Technical Review Panel on human resources for health\n\n  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n  **Positive TRP comments**                                                                                                                        **Negative TRP comments**\n  ------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------\n  Proposal could make a significant contribution to the underlying structural difficulties preventing adequate response to AIDS, Tb and malaria\\   Insufficient assessment and planning of HR issues\\\n  Link to specific disease well articulated\\                                                                                                       Limited human resources available -- capacity insufficient to achieve goals\\\n  Standardization of training curricula\\                                                                                                           Insufficient situational analysis in terms of human resources\\\n  Involvement of training institution\\                                                                                                             Training strategies lack an accurate description of partners/providers\\\n  Involvement of private sector\\                                                                                                                   Unclear number of trainees and costs\\\n  National code of practice for health workers being developed to reduce stigma\\                                                                   Inadequately addressing motivation issues\n  Key role of non-health personnel acknowledged                                                                                                    \n\n  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\nSource: \\[15, 16\\]\n\nHuman resources in integrated and health system proposals\n---------------------------------------------------------\n\nIn Round 4, the guidelines introduce a specific option to address cross-cutting health systems issues, including human resources constraints, in an integrated proposal.",
            "act": 0.12436841428279877
        },
        {
            "text": "I have to stay here.",
            "act": 0.12385332584381104
        },
        {
            "text": "A temporal and compartment switch from active to inhibitory GSK3 phosphorylation smoothens the SMAD-GLI1 relay and reduces cell-to-cell heterogeneity on GLI1 activation {#Sec7}\n------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\nBased on the above results, we constructed an expanded network for TGF-\u03b2 induced SNAIL1 expression (Fig.",
            "act": 0.11675508320331573
        },
        {
            "text": "Ground floor, 3rd office on the right.",
            "act": 0.11455833911895752
        },
        {
            "text": "I can\u2019t do it.",
            "act": 0.11031186580657959
        },
        {
            "text": "I need to know the truth.",
            "act": 0.10873836278915405
        },
        {
            "text": "But I can't.",
            "act": 0.10795678198337555
        },
        {
            "text": "I thought, \u2018Oh my God, I'm getting so deeply relaxed here.",
            "act": 0.10686549544334412
        },
        {
            "text": "---------------------------------------------------------------------------------------------------------------------------------------------\n  Simple                Trust    Experience                                                                                           \n  --------------------- -------- ------------ --------- --------- -------- --------- --------- --------- -------- --------- --------- ---------\n  **Medication name**                                                                                                                 \n\n  \\                     0.20     0.796        0.938     0.861     0.18     0.825     0.927     0.873     0.18     0.845     0.921     0.881\n\n  \\                     *0.40*   *0.896*      *0.904*   *0.900*   *0.24*   *0.861*   *0.916*   *0.888*   *0.24*   *0.876*   *0.908*   *0.892*\n\n  \\                     0.60     0.950        0.812     0.875     0.30     0.898     0.906     0.902     0.30     0.900     0.891     0.896\n\n  \\                     0.80     0.972        0.732     0.835     0.36     0.908     0.887     0.897     0.36     0.933     0.867     0.899\n\n  **Medication type**                                                                                                                 \n\n  \\                     0.20     0.610        0.916     0.733     0.18     0.655     0.892     0.755     0.18     0.662     0.872     0.752\n\n  \\                     *0.40*   *0.732*      *0.790*   *0.760*   *0.24*   *0.691*   *0.843*   *0.759*   *0.24*   *0.703*   *0.817*   *0.756*\n\n  \\                     0.60     0.851        0.541     0.661     0.30     0.736     0.792     0.763     0.30     0.756     0.773     0.764\n\n  \\                     0.80     0.945        0.382     0.544     0.36     0.776     0.744     0.760     0.36     0.783     0.684     0.730\n  ---------------------------------------------------------------------------------------------------------------------------------------------\n\n^a^precision\n\n^b^recall\n\n^c^F-measure\n\n^d^threshold\n\n###### \n\nBaseline Results of medical named entity annotation corresponding to the correction task (the pre-determined threshold and its corresponding P^a^, R^b^, and F^c^ for each column are italicized).",
            "act": 0.10578827559947968
        },
        {
            "text": "--------------------------------------------------------------------------------------------------------------------------------------------\n  \u2009                                                     Persons with hip fracture\\   *P*    Persons without hip fracture\\   *n* tested   \n                                                        (*n* = 9)                           (*n* = 209)                                  \n  ----------------------------------------------------- ---------------------------- ------ ------------------------------- ------------ -----\n  Age, mean (range) years                               80 (56--92)                  0.18   75 (33--94)                     9            209\n\n  Men, *n* (%)                                          6 (67)                       0.50   105 (50)                        9            209\n\n  NIHSS, md (IQR)                                       5 (2--7)                     0.18   6 (3--11)                       9            209\n\n  Neglect, *n* (%)                                      2 (22)                       0.96   45 (22)                         9            209\n\n  Visual impairment, *n* (%)                            6 (67)                       0.04   52 (33)                         9            156\n\n  Persons who fell during the previous year, *n* (%)    5 (56)                       0.76   59 (39)                         9            156\n\n  Persons who fell at the stroke unit, *n* (%)          1 (11)                       0.84   17 (9)                          9            187\n\n  Persons with fractures before stroke onset, *n* (%)   2 (22)                       0.01   6 (4)                           9            156\n\n  MMSE, md (IQR)                                        21 (14--26)                  0.05   26 (21--28)                     9            152\n\n  BL: motor impairment upper ex, *n* (%)                7 (88)                       0.18   102 (64)                        8            159\n\n  BL: motor impairment lower ex, *n* (%)                5 (63)                       1      99 (62)                         8            159\n\n  BBS \\< 45, *n* (%)                                    6 (75)                       0.28   77 (50)                         8            154\n\n  TUG \u2265 14 seconds, *n* (%)                             4 (80)                       0.05   37 (34)                         5            110\n\n  SWWT, *n* (%)                                         2 (29)                       0.02   7 (6)                           7            118\n  --------------------------------------------------------------------------------------------------------------------------------------------\n\nNIHSS: National Institutes of Health Stroke Scale; Md: median; IQR: interquartile range; MMSE: Mini-Mental State Examination BL: Birgitta Lindmark motor assessment scale; BBS: Berg Balance Scale; TUG: Timed Up & Go; SWWT: Stops Walking When Talking.",
            "act": 0.10540540516376495
        },
        {
            "text": "Don\u2019t rush into this decision.",
            "act": 0.1036946028470993
        },
        {
            "text": "\u0422\u0435\u0445.",
            "act": 0.10223478078842163
        },
        {
            "text": "To prepare for the quick change at the end, I had to remember to place my farm clothes offstage right during intermission, and I had to have my shoelaces loosened in Act II.",
            "act": 0.10153864324092865
        },
        {
            "text": "I can\u2019t even.",
            "act": 0.09998175501823425
        },
        {
            "text": "---------------------------------------------------------------------------------------------------------------------------------------------\n  Simple                Trust    Experience                                                                                           \n  --------------------- -------- ------------ --------- --------- -------- --------- --------- --------- -------- --------- --------- ---------\n  **Medication name**                                                                                                                 \n\n  \\                     0.20     0.694        0.931     0.796     0.18     0.835     0.887     0.860     0.18     0.807     0.895     0.849\n\n  \\                     *0.40*   *0.864*      *0.879*   *0.871*   *0.24*   *0.864*   *0.879*   *0.871*   *0.24*   *0.869*   *0.874*   *0.872*\n\n  \\                     0.60     0.920        0.815     0.865     0.30     0.869     0.874     0.871     0.30     0.885     0.854     0.870\n\n  \\                     0.80     0.955        0.696     0.805     0.36     0.916     0.819     0.865     0.36     0.910     0.820     0.863\n\n  **Medication type**                                                                                                                 \n\n  \\                     0.20     0.431        0.879     0.579     0.18     0.632     0.781     0.699     0.18     0.583     0.800     0.675\n\n  \\                     *0.40*   *0.698*      *0.763*   *0.729*   *0.24*   *0.698*   *0.763*   *0.729*   *0.24*   *0.711*   *0.751*   *0.731*\n\n  \\                     0.60     0.831        0.598     0.696     0.30     0.709     0.745     0.727     0.30     0.756     0.703     0.729\n\n  \\                     0.80     0.911        0.396     0.552     0.36     0.819     0.608     0.698     0.36     0.816     0.614     0.700\n  ---------------------------------------------------------------------------------------------------------------------------------------------\n\n^a^precision\n\n^b^recall\n\n^c^F-measure\n\n^d^threshold\n\nResults of Correction Task\n--------------------------\n\nThe results of the correction task, its corresponding correction baseline, and the results of combined judgments are presented in [Tables 5](#table5){ref-type=\"table\"} and [6](#table6){ref-type=\"table\"}, respectively.",
            "act": 0.0978308692574501
        },
        {
            "text": "About a company of EPR squads were at the sector headquarter in Rajshahi.",
            "act": 0.09623537212610245
        },
        {
            "text": "As the Bavarian champions, the club was entitled to enter the promotion round to the 2.",
            "act": 0.09051513671875
        },
        {
            "text": "---------------------------------------------------------------------------------------------------------------------------------------------\n  Simple                Trust    Experience                                                                                           \n  --------------------- -------- ------------ --------- --------- -------- --------- --------- --------- -------- --------- --------- ---------\n  **Medication name**                                                                                                                 \n\n  \\                     0.20     0.712        0.934     0.808     0.18     0.839     0.891     0.864     0.18     0.774     0.908     0.835\n\n  \\                     *0.40*   *0.868*      *0.887*   *0.877*   *0.24*   *0.868*   *0.887*   *0.877*   *0.24*   *0.872*   *0.887*   *0.879*\n\n  \\                     0.60     0.909        0.788     0.844     0.30     0.870     0.887     0.878     0.30     0.881     0.876     0.879\n\n  \\                     0.80     0.956        0.655     0.778     0.36     0.899     0.803     0.848     0.36     0.894     0.809     0.849\n\n  **Medication type**                                                                                                                 \n\n  \\                     0.20     0.473        0.879     0.615     0.18     0.627     0.724     0.672     0.18     0.594     0.779     0.674\n\n  \\                     *0.40*   *0.669*      *0.704*   *0.686*   *0.24*   *0.669*   *0.704*   *0.686*   *0.24*   *0.668*   *0.698*   *0.683*\n\n  \\                     0.60     0.737        0.519     0.609     0.30     0.670     0.700     0.685     0.30     0.681     0.664     0.673\n\n  \\                     0.80     0.890        0.358     0.510     0.36     0.726     0.550     0.626     0.36     0.717     0.558     0.628\n  ---------------------------------------------------------------------------------------------------------------------------------------------\n\n^a^precision\n\n^b^recall\n\n^c^F-measure\n\n^d^threshold\n\nFurthermore, we analyzed the practical significance of these improvements by calculating the F-measure of medication name and medication type for each unique judgment (the total number of unique judgments was 735) and its corresponding 5 correction judgments.",
            "act": 0.09018312394618988
        },
        {
            "text": "Now stop.",
            "act": 0.08976351469755173
        },
        {
            "text": "No, I couldn't.",
            "act": 0.08957614004611969
        },
        {
            "text": "------------------------- ---------- ---------- ------------- ---------------\n  *D*---H\u00b7\u00b7\u00b7*A*             *D*---H    H\u00b7\u00b7\u00b7*A*    *D*\u00b7\u00b7\u00b7*A*     *D*---H\u00b7\u00b7\u00b7*A*\n  N1---H1*N*\u00b7\u00b7\u00b7O1           0.90 (2)   1.74 (2)   2.5411 (15)   147 (2)\n  C1---H1*B*\u00b7\u00b7\u00b7O3^i^        0.98       2.57       3.4461 (18)   149\n  C8---H8*B*\u00b7\u00b7\u00b7O2^ii^       0.98       2.62       3.3478 (17)   132\n  C10---H10\u00b7\u00b7\u00b7O1^iii^       0.95       2.56       3.2035 (16)   125\n  C13---H13\u00b7\u00b7\u00b7O2^iv^        0.95       2.46       3.3950 (17)   170\n  C15---H15*A*\u00b7\u00b7\u00b7*Cg*1^v^   0.99       2.74       3.618 (2)     149\n  ------------------------- ---------- ---------- ------------- ---------------\n\nSymmetry codes: (i) \u2212*x*+1, \u2212*y*, \u2212*z*; (ii) \u2212*x*+1, *y*, \u2212*z*+1/2; (iii) \u2212*x*+1/2, *y*+1/2, \u2212*z*+1/2; (iv) *x*, \u2212*y*+1, *z*+1/2; (v) \u2212*x*+1/2, \u2212*y*+1/2, \u2212*z*+1.",
            "act": 0.08722739666700363
        },
        {
            "text": "ICF stadium, Kambar Arangam bus stop), ICF, Chennai - 38.",
            "act": 0.08605515956878662
        },
        {
            "text": "I\u2019m off and running, and I\u2019m not turning back.",
            "act": 0.08592921495437622
        },
        {
            "text": "1   2   3   4   5   6   7   8\n---------------------------------\n0:  8  12  15  20  26  28  37  48\n1:----  4   7  12  18  20  29  40\n2:--------  3   8  14  16  25  36\n3:------------  5  11  13  22  33\n4:----------------  6   8  17  28\n5:--------------------  2  11  22\n6:------------------------  9  20\n7:---------------------------- 11\n\nActually, looking at it now, I see I have to rephrase my question.",
            "act": 0.08566594123840332
        },
        {
            "text": "[](pone.0179624.t007){#pone.0179624.t007g}\n\n  ------------------- -------------------- ----------------- -------------------- ------------------ ------------------- --------- ----------\n                      Rostrum              Genu              Rostral body         Anterior midbody   Posterior midbody   Isthmus   Splenium\n  Rostrum                                                                                                                          \n  Genu                .286                                                                                                         \n  Rostral body        [**7.0E-07**]{.ul}   [**.004**]{.ul}                                                                         \n  Anterior midbody    .164                 1.000             [**2.0E-04**]{.ul}                                                    \n  Posterior midbody   .500                 1.000             [**4.1E-04**]{.ul}   1.000                                            \n  Isthmus             1.000                .582              [**2.6E-06**]{.ul}   .168               .560                          \n  Splenium            .077                 1.000             [**1.4E-03**]{.ul}   1.000              1.000               .050      \n  ------------------- -------------------- ----------------- -------------------- ------------------ ------------------- --------- ----------\n\nValues present Bonferroni-corrected *P* values.",
            "act": 0.0828489363193512
        }
    ],
    "low_act_samples": [
        {
            "text": "Can you explain your reasoning again?",
            "act": 0.0
        },
        {
            "text": "The facts seem to keep getting in the way of your theory .",
            "act": 0.0
        },
        {
            "text": ".",
            "act": 0.0
        },
        {
            "text": ".",
            "act": 0.0
        },
        {
            "text": ".",
            "act": 0.0
        },
        {
            "text": "[Bad facts!",
            "act": 0.0
        },
        {
            "text": "BAD!]",
            "act": 0.0
        },
        {
            "text": "hooray4anything\n\nWhat I'm trying to say is that nobody really knows what Oswald was doing or what he believed because he got shot too quickly to know and his motivations too murky.",
            "act": 0.0
        },
        {
            "text": "It's also hard to know because there's way too many stories out there about the whole thing but most of them do tend towards the JFK being killed as a result of him being blamed for allowing Castro to take over Cuba, whether it be the mob, anti-Castro-ites, or the CIA.",
            "act": 0.0
        },
        {
            "text": "None of those three could be considered lefty.",
            "act": 0.0
        },
        {
            "text": "So, in other words, calling Oswald one thing or another is silly because nobody knows and if there is a meme out there saying he was some crazy-ass liberal, then it shows just how desperate some people are to twist history into their weird little worldviews but facts are stubborn little things.",
            "act": 0.0
        },
        {
            "text": "fuflans\n\nsimon, please list those left wing assassinations of which you speak?",
            "act": 0.0
        },
        {
            "text": "cause i'm pretty up the news and can't think of any recent ones.",
            "act": 0.0
        },
        {
            "text": "assassinations in this country in the last 30 years have been right wing christian nutjobs, right wing islamic nutjobs and random troubled students.",
            "act": 0.0
        },
        {
            "text": "SorosBot\n\nThere's none that I can think of since the guy who killed McKinley, 110 years ago.",
            "act": 0.0
        },
        {
            "text": "Hell, the guy who shot the single right-winger who was the victim of an assassination attempt in the wave of assassinations of left-wing figures in the 60s and 70s turned out to be a nutcase who just wanted to assassinate somebody important so he would become famous; and likewise Hinkley was just an insane stalker.",
            "act": 0.0
        },
        {
            "text": "Jukesgrrl\n\nU of A basketball game scheduled for today has been canceled.",
            "act": 0.0
        },
        {
            "text": "That's as serious as shit gets here in Tucson.",
            "act": 0.0
        },
        {
            "text": "jim89048\n\nEven MSNBC stopped their weekend prison marathon to run with this, so yeah, pretty serious.",
            "act": 0.0
        },
        {
            "text": "luke_warm\n\nIt's in his second video where he talks about the constitution and \"apprehending\" the current slate of treasonous laws.",
            "act": 0.0
        },
        {
            "text": "But yeah, he's batshit.",
            "act": 0.0
        },
        {
            "text": "The judge who was assassinated was Chief Judge John Roll of the U.S. District Court for the District of Arizona.",
            "act": 0.0
        },
        {
            "text": "He had received death threats in the past from \u2026 guess!",
            "act": 0.0
        },
        {
            "text": "\u2026 talk-show listeners because he allowed a lawsuit by undocumented immigrants to go past summary judgment, and god help you if you do anything good for a Brown.",
            "act": 0.0
        },
        {
            "text": "So now we have not only had an attack on a Congresswoman (probably) because of her political affiliation but also a literal attack on judicial independence.",
            "act": 0.0
        },
        {
            "text": "In February, when U.S. District Judge John Roll presided over a $32 million civil-rights lawsuit filed by illegal immigrants against an Arizona rancher, the Marshals Service was anticipating the fallout.",
            "act": 0.0
        },
        {
            "text": "When Roll ruled the case could go forward, [Arizona U.S.",
            "act": 0.0
        },
        {
            "text": "Marshal] Gonzales said talk-radio shows cranked up the controversy and spurred audiences into making threats.",
            "act": 0.0
        },
        {
            "text": "In one afternoon, Roll logged more than 200 phone calls.",
            "act": 0.0
        },
        {
            "text": "Callers threatened the judge and his family.",
            "act": 0.0
        },
        {
            "text": "They posted personal information about Roll online.",
            "act": 0.0
        },
        {
            "text": "\"They said, 'We should kill him.",
            "act": 0.0
        },
        {
            "text": "He should be dead,' \" Gonzales said.",
            "act": 0.0
        },
        {
            "text": "Roll, who is the chief federal judge in Arizona, said both he and his wife were given a protection detail for about a month.",
            "act": 0.0
        },
        {
            "text": "\"It was unnerving and invasive.",
            "act": 0.0
        },
        {
            "text": ".",
            "act": 0.0
        },
        {
            "text": ".",
            "act": 0.0
        },
        {
            "text": ".",
            "act": 0.0
        },
        {
            "text": "By its nature it has to be,\" Roll said, adding that they were encouraged to live their lives as normally as possible.",
            "act": 0.0
        },
        {
            "text": "\"It was handled very professionally by the Marshals Service.\"",
            "act": 0.0
        },
        {
            "text": "At the end of the month, Roll said four key men had been identified as threat makers.",
            "act": 0.0
        },
        {
            "text": "The Marshals Service left to him the decision to press charges but recommended against it.",
            "act": 0.0
        },
        {
            "text": "Roll said he had no qualms about following their advice.",
            "act": 0.0
        },
        {
            "text": "AZ_Transplant\n\nI worked in her office last year.",
            "act": 0.0
        },
        {
            "text": "I only met her a few times, but she she was always really genuine and kind.",
            "act": 0.0
        },
        {
            "text": "I hope she pulls through.",
            "act": 0.0
        },
        {
            "text": "It's not a particularly common name, is it?",
            "act": 0.0
        },
        {
            "text": "Photo must be from 2010 festival, since the 2011 one is not scheduled until March.",
            "act": 0.0
        },
        {
            "text": "karen\n\nYeah that's what I was thinking.",
            "act": 0.0
        },
        {
            "text": "EdFlintstone\n\nSarah save your bullshit sympathy post on fucking facebook.",
            "act": 0.0
        }
    ]
}